Estimation of Serum CD200 and CD200R1 Levels in a Sample of Iraqi Women with Breast Cancer: Their Role as Diagnostic and Prognostic Markers

Breast cancer is a disease in which cells in the breast grow out of control. CD200 is a cell surface glycoprotein expressed on many cells, it belongs to the immunoglobulin family (Ig) and have a great role in the regulation of inflammation in autoimmunity. CD200 is the ligand for CD200R1 receptor. To determine if serum level of CD200 and its receptor CD200R1 can be used as a diagnostic and prognostic marker in patients with breast cancer.This case control study was carried out at Oncology Teaching Hospital – Medical city in Baghdad. Six groups were enrolled, four groups were confirmed with breast cancer stage (I, II, III and IV), fifth group (benign) and sixth group was control (healthy individual). Serum is divided to measure CD200 and CD200R1 by utilizing quantitative sandwich enzyme-linked immunosorbent assay (ELISA) Kits. Serum level of CD200 was significantly different (P=0.000088) between breast cancer patients and control only, serum level of CD200 increases with disease stage and there is a significant positive correlation. Serum level of CD200R1 was different with stage, although the differences were not significant but the level of CD200R1 is lower in stage 4 patients than other stages. Serum CD200 level can be used as a diagnostic marker for breast cancer. Serum level of CD200R1 can be used as a prognostic marker

Download Full-text

C-C motif chemokine ligand 5 and C-C chemokine receptor type 5: possible diagnostic application in breast cancer patients

Acta Biochimica Polonica ◽

10.18388/abp.2020_5402 ◽

2020 ◽

Author(s):

Emilia Dąbrowska ◽

Andrzej Przylipiak ◽

Monika Zajkowska ◽

Barbara Maria Piskór ◽

Aleksandra Borowik-Zaręba ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

High Specificity ◽

Disease Stage ◽

Enzyme Linked Immunosorbent Assay ◽

Advanced Tumor Stage ◽

Breast Cancer Patients ◽

Early Screening ◽

Roc Curve Analysis ◽

Advanced Tumor

The chemokine CCL5 and its receptor CCR5 play important roles in cancer invasion and metastasis. Based on our knowledge, our results were the first that presented the diagnostic usefulness of CCL5 and CCR5 in breast cancer (BC) patients, based on receiver operating characteristic (ROC) curve analysis. We wished to examine further if CCL5 and CCR5 are appropriate to be applied as BC markers for early screening. Values of tested parameters in patients’ plasma were determined by CMIA method (Chemiluminescent Microparticle Immunoassay, CA 15-3) as well as by ELISA method (Enzyme-Linked Immunosorbent Assay, CCL5 and CCR5). Levels of CCL5 in the plasma were markedly increased, while those of CCR5 were remarkably lower in BC patients when compared to the control groups. Moreover, higher levels of CCL5 in BC corresponded to advanced tumor stage, while the levels of CCR5 decreased with increasing the disease stage. CCL5 concentration was characterized by high sensitivity (SE) (68.04%) and high specificity (SP) (100.00%) in the BC patients. Results indicated that area under the curve (AUC) corresponding to CCL5 (0.8116) had a higher value than this corresponding to CA 15-3. The AUC value of CCL5 was significantly increased in the early phase of BC (stage I – 0.7089; stage II – 0.8313). The maximum range in the BC patients was observed for the combined analysis of the tested measurands with CA 15-3 (0.8335). In conclusion, our research indicates that examination of plasma CCL5 and CCR5 may be useful in BC diagnosis at the early stage of the disorder, especially when combined with CA 15-3.

Download Full-text

Down-Regulation of a Cell-Surface Glycoprotein Correlated with Rearrangement of Chromosome 1 in Human Breast Cancer Cells

Familial Cancer Control ◽

10.1007/978-3-642-77582-6_5 ◽

1992 ◽

pp. 17-21

Author(s):

S. Ashraf Imam ◽

Laura A. Mills ◽

Sen Pathak ◽

Clive R. Taylor

Keyword(s):

Breast Cancer ◽

Cell Surface ◽

Cancer Cells ◽

Human Breast Cancer ◽

Surface Glycoprotein ◽

Chromosome 1 ◽

Human Breast Cancer Cells ◽

Down Regulation ◽

Cell Surface Glycoprotein ◽

A Cell

Download Full-text

Clinical impact of PTEN methylation status as a prognostic marker for breast cancer

Journal of Genetic Engineering and Biotechnology ◽

10.1186/s43141-021-00169-4 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Amal Ramadan ◽

Maha Hashim ◽

Amr Abouzid ◽

Menha Swellam

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Tumor Markers ◽

Prognostic Marker ◽

Methylation Status ◽

Clinical Impact ◽

Breast Cancer Patients ◽

Duct Carcinoma ◽

Cancer Group ◽

And Control

Abstract Background Aberrant DNA methylation of phosphatase and tensin homolog (PTEN) gene has been found in many cancers. The object of this study was to evaluate the clinical impact of PTEN methylation as a prognostic marker in breast cancer. The study includes 153 newly diagnosed females, and they were divided according to their clinical diagnosis into breast cancer patients (n = 112) and females with benign breast lesion (n = 41). A group of healthy individuals (n = 25) were recruited as control individuals. Breast cancer patients were categorized into early stage (0–I, n = 48) and late stage (II–III, n = 64), and graded into low grade (I–II, n = 42) and high grade (III, n = 70). Their pathological types were invasive duct carcinoma (IDC) (n = 66) and duct carcinoma in situ (DCI) (n = 46). Tumor markers (CEA and CA15.3) were detected using ELISA. DNA was taken away from the blood, and the PTEN promoter methylation level was evaluated using the EpiTect Methyl II PCR method. Results The findings revealed the superiority of PTEN methylation status as a good discriminator of the cancer group from the other two groups (benign and control) with its highest AUC and increased sensitivity (96.4%) and specificity (100%) over tumor markers (50% and 84% for CEA and 49.1% and 86.4% for CA15.3), respectively. The frequency of PTEN methylation was 96.4% of breast cancer patients and none of the benign and controls showed PTEN methylation and the means of PTEN methylation (87 ± 0.6) were significantly increased in blood samples of breast cancer group as compared to both benign and control groups (25 ± 0.7 and 12.6 ± 0.3), respectively. Methylation levels of PTEN were higher in the blood of patients with ER-positive than in patients with ER-negative cancers (P = 0.007) and in HER2 positive vs. HER2 negative tumors (P = 0.001). The Kaplan-Meier analysis recognizes PTEN methylation status as a significant forecaster of bad progression-free survival (PFS) and overall survival (OS), after 40 months follow-up. Conclusions PETN methylation could be supposed as one of the epigenetic aspects influencing the breast cancer prognosis that might foretell more aggressive actions and worse results in breast cancer patients.

Download Full-text

Clinical Significance of Annexin A2 Expression in Breast Cancer Patients

Cancers ◽

10.3390/cancers13010002 ◽

2020 ◽

Vol 13 (1) ◽

pp. 2

Author(s):

Lee D. Gibbs ◽

Kelsey Mansheim ◽

Sayantan Maji ◽

Rajesh Nandy ◽

Cheryl M. Lewis ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Clinical Significance ◽

Cell Lines ◽

Breast Cancer Subtypes ◽

Enzyme Linked Immunosorbent Assay ◽

Breast Cancer Patients ◽

Serum Samples ◽

Cancer Subtypes ◽

Tumor Tissues

Increasing evidence suggests that AnxA2 contributes to invasion and metastasis of breast cancer. However, the clinical significance of AnxA2 expression in breast cancer has not been reported. The expression of AnxA2 in cell lines, tumor tissues, and serum samples of breast cancer patients were analyzed by immunoblotting, immunohistochemistry, and enzyme-linked immunosorbent assay, respectively. We found that AnxA2 was significantly upregulated in tumor tissues and serum samples of breast cancer patients compared with normal controls. The high expression of serum AnxA2 was significantly associated with tumor grades and poor survival of the breast cancer patients. Based on molecular subtypes, AnxA2 expression was significantly elevated in tumor tissues and serum samples of triple-negative breast cancer (TNBC) patients compared with other breast cancer subtypes. Our analyses on breast cancer cell lines demonstrated that secretion of AnxA2 is associated with its tyrosine 23 (Tyr23) phosphorylation in cells. The expression of non-phosphomimetic mutant of AnxA2 in HCC1395 cells inhibits its secretion from cells compared to wild-type AnxA2, which further suggest that Tyr23 phosphorylation is a critical step for AnxA2 secretion from TNBC cells. Our analysis of AnxA2 phosphorylation in clinical samples further confirmed that the phosphorylation of AnxA2 at Tyr23 was high in tumor tissues of TNBC patients compared to matched adjacent non-tumorigenic breast tissues. Furthermore, we observed that the diagnostic value of serum AnxA2 was significantly high in TNBC compared with other breast cancer subtypes. These findings suggest that serum AnxA2 concentration could be a potential diagnostic biomarker for TNBC patients.

Download Full-text

MEDALT: single-cell copy number lineage tracing enabling gene discovery

Genome Biology ◽

10.1186/s13059-021-02291-5 ◽

2021 ◽

Vol 22 (1) ◽

Cited By ~ 2

Author(s):

Fang Wang ◽

Qihan Wang ◽

Vakul Mohanty ◽

Shaoheng Liang ◽

Jinzhuang Dou ◽

...

Keyword(s):

Breast Cancer ◽

Single Cell ◽

Copy Number ◽

Speciation Analysis ◽

Population Based ◽

Lineage Tracing ◽

Breast Cancer Patients ◽

Lineage Tree ◽

History Of ◽

A Cell

AbstractWe present a Minimal Event Distance Aneuploidy Lineage Tree (MEDALT) algorithm that infers the evolution history of a cell population based on single-cell copy number (SCCN) profiles, and a statistical routine named lineage speciation analysis (LSA), whichty facilitates discovery of fitness-associated alterations and genes from SCCN lineage trees. MEDALT appears more accurate than phylogenetics approaches in reconstructing copy number lineage. From data from 20 triple-negative breast cancer patients, our approaches effectively prioritize genes that are essential for breast cancer cell fitness and predict patient survival, including those implicating convergent evolution.The source code of our study is available at https://github.com/KChen-lab/MEDALT.

Download Full-text

Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias

Biology ◽

10.3390/biology10070629 ◽

2021 ◽

Vol 10 (7) ◽

pp. 629

Author(s):

Snjezana Janjetovic ◽

Philipp Lohneis ◽

Axel Nogai ◽

Derya Balci ◽

Leo Rasche ◽

...

Keyword(s):

Plasma Cell ◽

Molecular Mechanisms ◽

Biological Characteristics ◽

Surface Glycoprotein ◽

Cell Surface Glycoprotein ◽

Similar Frequency ◽

Cytogenetic Aberrations ◽

A Cell ◽

Plasma Cell Dyscrasias ◽

Extramedullary Plasmocytoma

Background: Extramedullary plasma cell (PC) disorders may occur as extramedullary disease in multiple myeloma (MM-EMD) or as primary extramedullary plasmocytoma (pEMP)/solitary osseous plasmocytoma (SOP). In this study, we aimed to obtain insights into the molecular mechanisms of extramedullary spread of clonal PC. Methods: Clinical and biological characteristics of 87 patients with MM-EMD (n = 49), pEMP/SOP (n = 20) and classical MM (n = 18) were analyzed by using immunohistochemistry (CXCR4, CD31, CD44 and CD81 staining) and cytoplasmic immunoglobulin staining combined with fluorescence in situ hybridization (cIg-FISH). Results: High expression of CD44, a cell-surface glycoprotein involved in cell-cell interactions, was significantly enriched in MM-EMD (90%) vs. pEMP/SOP (27%) or classical MM (33%) (p < 0.001). In addition, 1q21 amplification by clonal PC occurred at a similar frequency of MM-EMD (33%), pEMP/SOP (57%) and classical MM (44%). Conversely, del(17p13), t(4;14) and t(14;16) were completely absent in pEMP/SOP. Besides this, 1q21 amplification was identified in 64% of not paraskeletal samples from MM-EMD or pEMP compared to 9% of SOP or paraskeletal MM-EMD/pEMP and 44% of classical MM samples, respectively (p = 0.02). Conclusion: Expression of molecules involved in homing and cytogenetic aberrations differ between MM with or without EMD and pEMP/SOP.

Download Full-text

Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer

Journal of Clinical Medicine ◽

10.3390/jcm9124122 ◽

2020 ◽

Vol 9 (12) ◽

pp. 4122

Author(s):

Barbara Maria Piskór ◽

Andrzej Przylipiak ◽

Emilia Dąbrowska ◽

Iwona Sidorkiewicz ◽

Marek Niczyporuk ◽

...

Keyword(s):

Breast Cancer ◽

Area Under The Curve ◽

Disease Stage ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Early Stages ◽

Potential Marker ◽

Breast Cancer Biomarkers ◽

Diagnostic Usefulness ◽

Chemiluminescent Microparticle Immunoassay

Background: Stromelysins are potential breast cancer biomarkers. The aim of the study was to evaluate if plasma levels of selected metalloproteinases (MMPs) (stromelysin-1 (MMP-3) and stromelysin-10 (MMP-10)) and cancer antigen 15-3 (CA 15-3) used separately and in combination demonstrated diagnostic usefulness in breast cancer (BC). Methods: The study group consisted of 120 patients with BC, while the control group included 40 patients with benign breast cancer and 40 healthy individuals. Concentrations of MMP-3 and MMP-10 were determined by enzyme-linked immunosorbent assay; CA 15-3 was determined by chemiluminescent microparticle immunoassay. Results: In the group of patients with BC, the area under the curve (AUC) was significantly higher for all markers (except MMP-3) and all sets of markers. At the earliest disease stage, only MMP-10 had a significantly higher AUC (AUC = 0.8692, p < 0.001). Moreover, MMP-10 had the highest AUC (0.9166) among parameters tested separately. The highest AUC was observed for the combination of MMP-10 + CA 15-3 and MMP-3 + MMP-10 + CA 15-3 in line with disease progression (stage I 0.8884 and 0.8906, stage II 0.9244 and 0.9308, stages III + IV 0.9919 and 0.9944, respectively, p < 0.001 in all cases). Conclusions: The results suggest that MMP-10 could be a potential marker in early stages of BC. Moreover, plasma concentration of MMP-10 and MMP-3 in combination with CA 15-3 may improve diagnosis of this type of cancer.

Download Full-text